Implementation Advice: Proposed Scope in Therapeutic area: Prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer

The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. [...] CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials. [...] This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada. [...] At the request of the drug programs that participate in the CADTH reimbursement review processes, CADTH is convening an implementation advice panel to advise the drug programs on radiopharmaceuticals that can be used to identify patients eligible for treatment with Pluvicto for prostate cancer. [...] In addition to the clinical panellists and CADTH staff, representatives from public drug programs, the pan-Canadian Pharmaceutical Alliance, and the Canadian Association of Provincial Cancer Agencies may participate in the discussion and provide input in advance of the meeting on the topics for discussion.